Cargando…

MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma

The PI3K/AKT/mTOR axis promotes survival and is a frequently mutated pathway in cancer. Yet, inhibitors targeting this pathway are insufficient to induce cancer cell death as single agents in some contexts, including diffuse large B cell lymphoma (DLBCL). In these situations, combinations with inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, J. Scott, Tang, Sarah S., Ortiz, Veronica, Vo, Thanh-Trang, Fruman, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742099/ https://www.ncbi.nlm.nih.gov/pubmed/26460954

Ejemplares similares

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
por: Xie, Chencheng, et al.
Publicado: (2017)

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL
por: Gotesman, Moran, et al.
Publicado: (2018)

Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts
por: Brana, Irene, et al.
Publicado: (2017)

The nuclear import of ribosomal proteins is regulated by mTOR
por: Kazyken, Dubek, et al.
Publicado: (2014)

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma
por: Ghosh, Arindam P., et al.
Publicado: (2015)

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways
por: Jain, Payal, et al.
Publicado: (2017)

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
por: Litchfield, Lacey M., et al.
Publicado: (2020)

mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
por: Beagle, Brandon R., et al.
Publicado: (2014)

A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors
por: Yang, Shujie, et al.
Publicado: (2011)

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
por: Vaughan, Lynsey, et al.
Publicado: (2016)

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
por: Choudhary, G S, et al.
Publicado: (2015)

Regulation of mTOR complexes in long-lived growth hormone receptor knockout and Snell dwarf mice
por: Shi, Xiaofang, et al.
Publicado: (2022)

Akt and mTOR in B Cell Activation and Differentiation
por: Limon, Jose J., et al.
Publicado: (2012)

Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model
por: Hasan, Md. Nabiul, et al.
Publicado: (2014)

Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice
por: Bajwa, Preety, et al.
Publicado: (2016)

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
por: Brunen, Diede, et al.
Publicado: (2016)

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer
por: Haines, Eric, et al.
Publicado: (2018)

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
por: Gopalan, Priya K., et al.
Publicado: (2018)

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA(+) oral cancers
por: Yamaguchi, Kosuke, et al.
Publicado: (2016)

All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells
por: Gamper, Christopher J., et al.
Publicado: (2012)

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
por: Wagner, Verena, et al.
Publicado: (2014)

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma
por: Pongas, Georgios N., et al.
Publicado: (2017)

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
por: Heavey, Susan, et al.
Publicado: (2016)

Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics
por: Choudhary, Gaurav S., et al.
Publicado: (2015)

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
por: Sacco, Antonio, et al.
Publicado: (2010)

Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia
por: Buono, Roberta, et al.
Publicado: (2023)

Dual PI-3 kinase/mTOR inhibition impairs autophagy flux and induces cell death independent of apoptosis and necroptosis
por: Button, Robert W., et al.
Publicado: (2016)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020)

Mithramycin A induces apoptosis by regulating the mTOR/Mcl-1/tBid pathway in androgen-independent prostate cancer cells
por: Choi, Eun-Sun, et al.
Publicado: (2013)

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
por: Wu, Xianbo, et al.
Publicado: (2022)

mTOR-Dependent and Independent Survival Signaling by PI3K in B Lymphocytes
por: Kaileh, Mary, et al.
Publicado: (2016)

Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells
por: Burmi, Rajpal S., et al.
Publicado: (2018)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
por: Liu, Yang, et al.
Publicado: (2018)

Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation
por: Currier, Mark A., et al.
Publicado: (2017)

Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation
por: Keitel, Ulrike, et al.
Publicado: (2014)

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
por: Tarantelli, Chiara, et al.
Publicado: (2020)

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAF(V600E) patient-derived papillary thyroid carcinoma preclinical model
por: Duquette, Mark, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ms55296t606rrmj5nmub3clih6